Anti-ERBB2/ HER2/ CD340 monoclonal antibody

Anti-ERBB2/ HER2/ CD340 antibody for FACS & in-vivo assay

Target products collectionGo to HER2/ERBB2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T14597-Ab-1/ GM-Tg-hg-T14597-Ab-2Anti-Human HER2/ERBB2 monoclonal antibodyHuman
GM-Tg-rg-T14597-Ab-1/ GM-Tg-rg-T14597-Ab-2Anti-Rat HER2/ERBB2 monoclonal antibodyRat
GM-Tg-mg-T14597-Ab-1/ GM-Tg-mg-T14597-Ab-2Anti-Mouse HER2/ERBB2 monoclonal antibodyMouse
GM-Tg-cynog-T14597-Ab-1/ GM-Tg-cynog-T14597-Ab-2Anti-Cynomolgus/ Rhesus macaque HER2/ERBB2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T14597-Ab-1/ GM-Tg-felg-T14597-Ab-2Anti-Feline HER2/ERBB2 monoclonal antibodyFeline
GM-Tg-cang-T14597-Ab-1/ GM-Tg-cang-T14597-Ab-2Anti-Canine HER2/ERBB2 monoclonal antibodyCanine
GM-Tg-bovg-T14597-Ab-1/ GM-Tg-bovg-T14597-Ab-2Anti-Bovine HER2/ERBB2 monoclonal antibodyBovine
GM-Tg-equg-T14597-Ab-1/ GM-Tg-equg-T14597-Ab-2Anti-Equine HER2/ERBB2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T14597-Ab-1/ GM-Tg-hg-T14597-Ab-2; GM-Tg-rg-T14597-Ab-1/ GM-Tg-rg-T14597-Ab-2;
GM-Tg-mg-T14597-Ab-1/ GM-Tg-mg-T14597-Ab-2; GM-Tg-cynog-T14597-Ab-1/ GM-Tg-cynog-T14597-Ab-2;
GM-Tg-felg-T14597-Ab-1/ GM-Tg-felg-T14597-Ab-2; GM-Tg-cang-T14597-Ab-1/ GM-Tg-cang-T14597-Ab-2;
GM-Tg-bovg-T14597-Ab-1/ GM-Tg-bovg-T14597-Ab-2; GM-Tg-equg-T14597-Ab-1/ GM-Tg-equg-T14597-Ab-2
Products NameAnti-HER2/ERBB2 monoclonal antibody
Formatmab
Target NameHER2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Diagnostic target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-HER2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-INN-780Pre-Made Cinrebafusp Alfa P Alfaiosimilar, Bispecific, Anti-ERBB2/HER2;TNFRSF9 Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;ILA/4-1BB/CDw137 therapeutic antibody
    BiosimilarGMP-Bios-ab-230Pre-Made Gancotamab biosimilar, scFv, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
    BiosimilarGMP-Bios-ab-639Pre-Made Zanidatamab biosimilar, Bispecific mAb, Anti-ERBB2/HER2;ERBB2/HER2 Antibody: Anti-CD340/HER-2/MLN 19/NEU/NGL/TKR1/VSCN2;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
    BiosimilarGMP-Bios-INN-1055Pre-Made Zanidatamab Zovodotin B Zovodotiniosimilar, Bispecific/Biparatopic, Anti-ERBB2/HER2;ERBB2/HER2 Therapeutic/Biparatopic Antibody Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2
    BiosimilarGMP-Bios-ab-500Pre-Made Runimotamab biosimilar, Bispecific mAb, Anti-ERBB2/HER2;CD3E Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;T3E/TCRE/IMD18 therapeutic antibody
    BiosimilarGMP-Bios-ab-335Pre-Made Margetuximab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
    BiosimilarGMP-Bios-ab-148Pre-Made Disitamab biosimilar, Whole mAb ADC, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
    BiosimilarGMP-Bios-ab-439Pre-Made Pertuzumab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
    BiosimilarGMP-Bios-ab-576Pre-Made Timigutuzumab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
    BiosimilarGMP-Bios-ab-667Pre-Made Fidasimtamab biosimilar, Whole mAb, Anti-PDCD1/PD-1;ERBB2/HER2 Antibody: Anti-CD279/PD1/SLEB2/hSLE1;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
    BiosimilarGMP-Bios-ab-023Pre-Made Anbenitamab biosimilar, Bispecific mAb: Anti-ERBB2 (Domain II);ERBB2 (Domain IV) therapeutic antibody
    BiosimilarGMP-Bios-INN-1030Pre-Made Trastuzumab Beta Biosimilar, Whole Mab, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibody
    BiosimilarGMP-Bios-ab-593Pre-Made Trastuzumab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
    BiosimilarGMP-Bios-INN-1033Pre-Made Trastuzumab Emtansine Biosimilar, Whole Mab Adc, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-ab-336Pre-Made Marstacimab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
    BiosimilarGMP-Bios-INN-1032Pre-Made Trastuzumab Duocarmazine Biosimilar, Whole Mab Adc, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-ab-645Pre-Made Zenocutuzumab biosimilar, Bispecific mAb, Anti-ERBB3/Erbb-3;ERBB2/HER2 Antibody: Anti-FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
    BiosimilarGMP-Bios-INN-804Pre-Made Disitamab Vedotin Biosimilar, Whole Mab Adc, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-ab-119Pre-Made Coprelotamab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
    BiosimilarGMP-Bios-INN-845Pre-Made Ertumaxomab Biosimilar, Bispecific, Anti-Cd3E;Erbb2 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
    BiosimilarGMP-Bios-INN-1031Pre-Made Trastuzumab Deruxtecan Biosimilar, Whole Mab Adc, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibody Drug Conjugate
    Target AntigenProducts DevelopingMulti-species ERBB2/ HER2/ CD340 VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-T14597-Ag-1erb-b2 receptor tyrosine kinase 2 (ERBB2) protein


    Target information

    Target IDGM-T14597
    Target NameHER2
    Gene ID2064,13866,24337,697573,403883,751824,505709,100054739
    Gene Symbol and Synonymsc-ERB-2,c-ERB2,c-erbB-2,c-erbB2,c-neu,CD340,erb2,Erbb-2,ERBB2,HER-2,HER-2/neu,HER2,HER2/neu,l11Jus8,mKIAA3023,MLN 19,MLN-19,NEU,NGL,p185(erbB2),p185erbB2,TKR1,VSCN2
    Uniprot AccessionP04626,P06494,O18735
    Uniprot Entry NameERBB2_HUMAN,ERBB2_RAT,ERBB2_CANLF
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Diagnostics Biomarker, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseBreast Cancer, Non-Small Cell Lung Cancer, gastric cancer, Lupus Glomerulonephritis
    Gene EnsemblENSG00000141736
    Target ClassificationCheckpoint-Immuno Oncology, Kinase

    The target: HER2, gene name: ERBB2, also named as CD340, HER-2, HER-2/neu, HER2, MLN 19, NEU, NGL, TKR1. This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.